Eli Lilly (LLY)

Executive Summary

Eli Lilly is a global pharmaceutical leader, renowned for its dominance in diabetes and obesity care, driven by the blockbuster GLP-1/GIP receptor agonist tirzepatide (Mounjaro/Zepbound). The company has seen exceptional revenue growth from tirzepatide approvals in type 2 diabetes and chronic weight management, positioning it as a top player in the high-demand metabolic disease market. Beyond metabolism, Lilly maintains a robust pipeline spanning oncology, immunology, and neuroscience, with over 2,600 drug candidates across modalities. Its deep research engine and commercial execution have yielded a strong portfolio of approved medicines, including Verzenio (breast cancer), Taltz (psoriasis), and Emgality (migraine). Looking ahead, Lilly's pipeline holds several high-value catalysts. Key near-term events include pivotal data readouts and regulatory decisions for next-generation therapies such as orforglipron (oral GLP-1), retatrutide (triple agonist), and donanemab (Alzheimer’s disease). The company's strategic investments in metabolic, neurodegenerative, and oncology assets, combined with its manufacturing scale and global reach, underpin a favorable outlook. With tirzepatide's market expansion and a rich pipeline, Lilly is well-positioned for sustained multiyear growth, though challenges include pricing pressures and competition from other obesity drugs.

Upcoming Catalysts (preview)

• Q3 2026Tirzepatide (Mounjaro/Zepbound) Phase 3 data in MASH (non-alcoholic steatohepatitis) - SYNERGY-NASH trial readout75% success
• Q1 2027Orforglipron (oral GLP-1) Phase 3 obesity program top-line results80% success
• Q2 2026Donanemab (Alzheimer's) EU regulatory decision on marketing authorization85% success